# Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)

> **NCT04106349** · — · ACTIVE_NOT_RECRUITING · sponsor: **Ipsen** · enrollment: 150 (estimated)

## Conditions studied

- Advanced or Metastatic Renal Cell Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04106349
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-03
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04106349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04106349, "Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04106349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*